Anika Revised PMA For Orthovisc Osteoarthritis Treatment Slated For July
This article was originally published in The Gray Sheet
Executive Summary
Anika Therapeutics is pursuing a multiple-treatment indication for its Orthovisc sodium hyaluronic-acid (HA) injectable treatment for osteoarthritis of the knee, the firm reports.
You may also be interested in...
Genzyme Biosurgery To Include Tissue Repair/Surgical Units, Biomatrix
Genzyme Tissue Repair's 26-person Carticel sales force could aid Biomatrix' marketing efforts for Synvisc following the merger of Genzyme Surgical Products, Genzyme Tissue Repair and Biomatrix to create a new company, Genzyme Biosurgery.
Genzyme Biosurgery To Include Tissue Repair/Surgical Units, Biomatrix
Genzyme Tissue Repair's 26-person Carticel sales force could aid Biomatrix' marketing efforts for Synvisc following the merger of Genzyme Surgical Products, Genzyme Tissue Repair and Biomatrix to create a new company, Genzyme Biosurgery.
Anika Revamps Orthovisc Knee Trials In Hopes Of Catching Rivals In Footrace
Anika Therapeutics will apply for an investigational device exemption from FDA this quarter to begin supplemental clinical trials in support of its rejected premarket approval application for Orthovisc hyalauronic-acid (HA) injectable treatment for osteoarthritis of the knee.